From Medical Oncology Division (MWR, MHGF, MK, JSWB, JVT, CUB, AM-E., SK, SW, JBAGH), Biotherapy Unit, Hospital Pharmacy (JH van den Berg, CN, MZ , SS), the divisions of pharmacy and pharmacology (BN, JH Beijnen), molecular oncology and immunology (IJ, TNS, JBAGH), biometrics (RK, LDVW, M. van Dijk, LGG-O. , LHMV, ATA, HT), psychosocial research and epidemiology (RMTH, VPR, WHH), radiology (FL) and surgical oncology (ACJA, WJH, MWJMW), Netherlands Cancer Institute, Department of Hematopoiesis, Sanquin Research Laboratory and Landsteiner (MH, CV) and Department of Medical Oncology, University Medical Center Amsterdam, Vrije Universiteit Amsterdam (AJME), Amsterdam, Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (RMTH), Department of Medical Oncology, University Medical Center Utrecht, University of Utrecht (KPMS), Trial and Data Center, Princess Max ima Center for Pediatric Oncology (HT) and Oncode Inst itute (TNS), Utrecht, Department of Health Technology and Services Research, University of Twente (VPR), and Department of Medical Oncology, Medical Spectrum Twente (DP) , Enschede, Department of Medical Oncology, Erasmus Medical Center, Rotterdam (AAMV), Department of Medical Oncology, University Medical Center Groningen, Groningen (GAPH), Department of Medical Oncology, Amphia Hospital, Breda (MAMS- B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (MJBA), the Department of Medical Oncology, Isala, Zwolle (J.-WBG), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (GV), the Departments of Medical Oncology (EK), Biomedical Data Sciences (MWJMW), Hematology (TNS) and Clinical Oncology (JBAGH), Leiden University Medical Center, Leiden, Department of Medical Oncology, Medical Center university Radboud, Nijmegen (M JB-S.), Department of Medical Oncology, Leeuwarden Medical Center, Leeuwarden (WEF), and ee Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (FWPJB) — all in the Netherlands; the Department of Oncology, National Cancer Immune Therapy Center (THB, Ö.M., JSG, IMN, TJM, RBH, EE, M. Donia, IMS) and the Department of Plastic Surgery (LRH), University Hospital from Copenhagen, Herlev, Denmark; and Melanoma Institute Australia, the University of Sydney Faculty of Medicine and Health and the Royal Prince Alfred Hospital, all in Sydney (ACJA).
Dr. Haanen can be contacted at [email protected] or at the Division of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands. Dr Svane can be contacted at [email protected] or at the National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Borgmester Ib Juuls Vej 25C, 5th fl., 2730 Herlev, Denmark.
